EU/3/18/2056: Orphan designation for the treatment of idiopathic pulmonary fibrosis
Table of contents
On 24 August 2018, orphan designation (EU/3/18/2056) was granted by the European Commission to Nogra Pharma Limited, Ireland, for (S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid (also known as GED-0507-34-Levo) for the treatment of idiopathic pulmonary fibrosis.
Treatment of idiopathic pulmonary fibrosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Nogra Pharma Limited
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: